US Stock Insider Trading | Spero Therapeutics disclosed 3 insider transactions on February 5

2026-02-24 00:54:20

On February 5, 2026, Spero Therapeutics (SPRO) disclosed three insider trading transactions. Executive Keutzer Timothy sold 24,200 shares on February 4, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 5, 2026	Executive	Keutzer Timothy	February 2, 2026	Sell	18,900	2.20	46,400
February 5, 2026	Executive	Keutzer Timothy	February 3, 2026	Sell	24,200	2.14	51,800
February 5, 2026	Executive	Keutzer Timothy	February 4, 2026	Sell	3,471	2.24	7,775.04
February 4, 2026	Executive	Rajavelu Esther	February 2, 2026	Sell	18,400	2.20	40,600
November 12, 2025	Executive	Rajavelu Esther	November 7, 2025	Sell	40,300	2.37	95,400
September 3, 2025	Director	Mahadevia Ankit	August 28, 2025	Sell	6,572	1.97	12,900
September 3, 2025	Executive	Keutzer Timothy	August 28, 2025	Sell	1,695	1.97	3,339.15
February 5, 2025	Executive	Rajavelu Esther	February 5, 2025	Sell	20,700	0.78	16,100
February 5, 2025	Director	Mahadevia Ankit	February 5, 2025	Sell	69,200	0.78	54,000
February 5, 2025	Executive	Shukla Sath	February 5, 2025	Sell	155,300	0.78	121,200

[Company Information]

Spero Therapeutics, Inc., formerly known as Spero Therapeutics, LLC, was incorporated in December 2013 under Delaware law. The company is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies for MDR bacterial infections. The company also owns a platform technology called “Potential Platform,” which it believes will develop drugs capable of expanding the spectrum and efficacy of existing antibiotics, including previously inactive antibiotics, to combat Gram-negative bacteria. The company believes that if these new products are successfully developed and approved, they will have a meaningful impact on the treatment of MDR infections in community and hospital settings and hold significant commercial potential.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.